Milla Pharmaceuticals successfully partnered with Athenex Pharmaceutical Division (APD) to release a generic version of Magnesium Sulfate in Water for Injection.

The U.S. Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) for Magnesium Sulfate Injection, which is currently on the ASHP Drug Shortages List . The product is intended to prevent and control seizures in preeclampsia and eclampsia, and the launch aims to address recent supply issues for the medication in the U.S. market. 

Erik Lazarich, President of the US Operations of the Alter Pharma Group and Director of Milla Pharmaceuticals, said, “By launching our Magnesium Sulfate Injection and providing this high-quality generic equivalent to patients in need, we directly contribute to the realization of our ambition to make affordable medicines available to all, whether that is in the EU or the US.” Jeffrey Yordon, President of APD, added, “We are very pleased to launch this important product with our partner Milla Pharmaceuticals. This launch will enable the product to be utilized by patients that desperately need the drug.”

For the full press release, click here.

This is the second ANDA commercialization for Milla Pharmaceuticals and the third for an Alter Pharma Group product in the U.S. market.